Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830367 | 0.85 | NPC1 (0.74) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6813729 | 0.84 | TDP1 (0.55) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6834460 | 0.83 | POLB (0.44) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6821776 | 0.80 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6818740 | 0.80 | RXFP1 (0.71) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6351992 | 0.80 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL6818931 | 0.78 | KMT2A (0.60) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6833885 | 0.78 | TDP1 (0.49) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL6833848 | 0.76 | KMT2A (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL6833933 | 0.76 | NPC1 (0.54) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NPC1 3778/4885RAB9A 4337/4885MEN1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.